NANOBODY CANDIDATE SELECTED BY BOEHRINGER INGELHEIM FOR DEVELOPMENT
(Thomson Reuters ONE) -
GHENT, Belgium, 8 December 2010 - Ablynx [Euronext Brussels: ABLX] today
announced that Boehringer Ingelheim has selected a Nanobody candidate for
development. This is the first development candidate emerging from the strategic
alliance which the companies entered into in 2007, and will result in a ?5
million milestone payment to Ablynx.
Ablynx and Boehringer Ingelheim entered into an agreement in September 2007 to
collaborate on the discovery, development and commercialisation of Nanobody
therapeutics across a range of areas including for example immunology, oncology
and respiratory diseases. The agreement allows for potential milestone payments
of up to ?125 million plus royalties to Ablynx for each Nanobody developed.
Boehringer Ingelheim is exclusively responsible for the development, manufacture
and commercialisation of any products resulting from the collaboration. Ablynx
retains certain co-promotion rights in Europe.
"We are delighted to see this first lead programme progressing into development,
just over three years since we entered into this collaboration with Boehringer
Ingelheim," said Dr Edwin Moses, CEO and Chairman of Ablynx. He added: "We are
particularly pleased as this Nanobody candidate represents a promising new and
innovative approach to potentially expand treatment options for cancer
patients."
-ends-
About Ablynx [Euronext Brussels: ABLX] - http://www.ablynx.com
Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused
on the discovery and development of Nanobodies, a novel class of therapeutic
proteins based on single-domain antibody fragments, for a range of serious and
life-threatening human diseases. The Company currently has over 250 employees.
Ablynx completed a successful IPO on Euronext Brussels [ABLX] on 7 November
2007 and raised ?50 million through an SPO in March 2010.
Ablynx is developing a portfolio of Nanobody-based therapeutics in a number of
major disease areas, including inflammation, thrombosis, oncology and
Alzheimer's disease. Ablynx now has over 25 programmes in its therapeutic
pipeline and there are five Nanobodies in clinical development. So far,
Nanobodies have been successfully generated against more than 220 different
protein targets including several complex targets such as chemokines, GPCRs, ion
channels and viruses, which are typically very difficult to address with
conventional monoclonal antibodies.
For more information, please contact Ablynx:
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Marieke Vermeersch
Investor Relations Manager
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:marieke.vermeersch(at)ablynx.com
Complete version of the press release:
http://hugin.info/137912/R/1470644/407546.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ablynx via Thomson Reuters ONE
[HUG#1470644]
Unternehmensinformation / Kurzprofil:
Datum: 08.12.2010 - 18:04 Uhr
Sprache: Deutsch
News-ID 49543
Anzahl Zeichen: 3918
contact information:
Town:
Ghent
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 420 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"NANOBODY CANDIDATE SELECTED BY BOEHRINGER INGELHEIM FOR DEVELOPMENT"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
